Research

Business

& finance

Biology molec & cellular

Technologies

informatics

Chemistry

Bioprocess & manufacturing

Drug discovery

Drug safety & pharmacovigilance

Biomarkers &

Drug development

Clinical trials

Regulatory

Molecular medicine

therapeutic areas

academic

pharmacoeconomics

DNA, RNA

sequencing

IT Hardware

small molecules

Cell cultures

toxicology

diagnostics

ADME Absorption Distribution Metabolism Excretion

Phase zero

GLP Good Lab practice

DOE NIH

genes

PCR

IT software

analytical chemistry

proof of concept

biomarker assays

pharmacokinetics

AKA microdosing

SBIR  DOD

genomics

qPCR

bioinformatics
more bioinformatics

chemical genetics

ADME/Tox

biomarker validation

Phase 1 drug safety

addressing
unmet  medical needs

friends & families

copy number variations

next gen sequencing data analysis

mammalian cell lines

pharmacogenetics

mechanisms of action

GMP Good Manufacturing Practice

collaboration

alliances

gene networks           

biomimetics

media optimization

toxicogenomics

Pharmacogenomics

adaptive clinical trial designs 

basic

collaboration

project mgt

gene expression

cheminformatics

protein production scale-up & manufacturing

idiosyncratic toxicities

personalized medicine

SNPs gene variations

protein characterization

in vitro pharmacology

hit to leads

GCP Good Clinical Practice

collaboration

innovation

epigenetics

microarrays

microarray data analysis

protein purification

predictive safety

lead optimization

Phase II attrition - reducing

haplotypes

gene expression profiling

organic synthesis

lyophilization

biomarker SOPs

animal models

Backup compounds for reducing Phase II risk 

microarrays in translational medicine

finance

seed capital 

gene disruption & manipulation

HTS high thruput screening

drug targets

risk management

clinical biomarkers

applied

finance

A rounds

comparative genomic hybridization

cytokines

cancer diagnostics trends   oncogenomics

targeted cancer therapy

 translational cancer medicine

cancer

finance

venture capital

next generation sequencing

combinatorial libraries

GPCRs more GPCRs

immunogenicity assessment

cell & tissue assays

CROs Clinical Research Organizations

finance

IPOs

genotyping

data mining
text mining

HDAC inhibitors

immunogenicity minimization

patient recruitment

finance

M&A mergers & acquisitions

Bayesian statistics for Phase III outcomes

Medicinal chemistry

ion channels

cancer biomarkers

protein formulations

clinical project management

cancer

precompetitive

finance

clinical trial budgets

microRNA

RNAI RNA interference

kinases

preclinical drug safety

vaccine adjuvants & delivery

Conducting Clinical Trials in Europe

finance

risk management

proteins

protein engineering

fragment based drug design

toxicokinetics optimization

drug delivery
RNAi delivery

protein structures

mass spectrometry

backup compounds for reducing Phase II risk

target validation

circulating tumor cells

protein delivery

cancer

legal

intellectual property

proteomics

NMR

structure based drug design

target evaluation

ICH International Conference on Harmonisation 

legal

patents

membrane proteins

in silico modeling
molecular modeling

RNAI  screening cellular pathways

Molecular diagnostics
next generation diagnostics

clinical research fraud

legal

trade secrets

protein protein interactions

process chemistry

virtual screening

Patient stratification, prognosis & screening

Bayesian statistics for Phase III outcomes: clinical forecasting

commercial potential

legal

patents expiration

protein arrays

data storage

GMP Good Manufacturing Practice

protease inhibitors

clinical diagnostics

INDs investigational new drug applications

improving R&D economics collaboratively

RNAi therapeutics

Direct to Consumer Genetic dx

infectious diseases R&D

IRBs institution review bds

infectious diseases

strategic resource mgt

protein expression

ontologies

protein therapeutics

infectious disease diagnostics

antibacterial drug dev

HIPAA Health Insurance Portability 

infectious diseases

phage display & therapeutic antibodies

data integration & Knowledge mgt

monoclonal antibodies
therapeutic antibodies

antiviral pipelines & competitive dynamics

infectious diseases

protein science technologies

peptide therapeutics

antibiotic R&D: drug resistance

infectious diseases

Best practices

molecular imaging & informatics

Vaccines & immunotherapeutics

biodefense diagnostics

biodefense anthrax, etc

infectious diseases

R&D

bio/pharma R&D

biomaterials & bioengineering

immunotherapeutics

therapeutics diabetes optimizing R&D

immunology

biotechnology

bio/pharma R&D statistics

flow cytometry

integrated R&D informatics

vaccine manufacturing

therapeutic antibodies

cardiotoxicity

obesity drug pipeline

metabolic

pharmaceuticals

live cell imaging

electronic notebooks

hepatotoxicity

clinical protocols

strategic hurdles to pharma success

LIMs Lab info mgt systems

improving study outcomes

pharma R&D productivity

nanoscience

adverse effects reporting

ophthalmological tx pipelines

expediting drug/bio dev

omes & omics

pathways analysis

neurogenomics

novel  therapeutics Alzheimers

IND submissions Inv New Drug Application

blood brain barrier

CNS

post -approval

portfolio management

systems biology

point of care diagnostics

neurotherapeutics

neurodegeneration

CNS

post approval risks

metabolic profiling

novel therapeutics pain

metabolic networks

cells & tissues

tissue microarrays

high content assays
high content analysis

cell therapies

quality control

regulatory compliance

stem cells

 biobanking

auditing techniques

IND submissions

outsourcing

drug dev Asia

Bayesian statistics

metabolic & inflammatory pipelines

inflammatory diseases

inflammation
metabolic

outsourcing

drug dev China

Biomedical imaging

outsourcing

drug dev Latin America

outsourcing chemistry

nutrigenomics

glycosciences

markets

combination drugs/diagnostics

markets

specialty pharmaceuticals

drug repositioning

NDAs New Drug Approvals

markets

drug repositioning AKA drug repurposing

DNA RNA

pipeline success

                     business/finance        

cells tissues

biomarkers

molecular medicine

therapeutic areas

latest revision

2009

25 June

proteins

technologies

informatics

chemistry

bioprocessing

drug discovery

drug safety

diagnostics

drug development

clinical trials

regulatory